A Study of PHST001 in Advanced Solid Tumors

Trial ID or NCT#

NCT06840886

Status

recruiting iconRECRUITING

Purpose

PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.

Official Title

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Oliver Dorigo, M.D., Ph.D.
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist, Medical oncologist, Gynecologic oncologist
Mary Lake Polan Professor
Kristin Leigh Bixel
Associate Professor of Obstetrics and Gynecology (Gynecologic Oncology)
Jonathan S Berek
Jonathan S Berek
Gynecologic oncologist
Laurie Kraus Lacob Professor
Amer Karam
Amer Karam
Gynecologic oncologist
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology
Talayeh Ghezelayagh
Instructor, Obstetrics & Gynecology - Gynecologic Oncology
Emily Clair McClung
Emily Clair McClung
Gynecologic oncologist
Clinical Assistant Professor, Obstetrics & Gynecology - Gynecologic Oncology

Contact us to find out if this trial is right for you.

Contact

Kayla Michelle McDaniel

SEND MESSAGE

View on ClinicalTrials.gov